STVN Earnings Prediction
The chart below shows how STVN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, STVN sees a +4.71% change in stock price 10 days leading up to the earnings, and a -2.09% change 10 days following the report. On the earnings day itself, the stock moves by +0.07%. This data can give you a slight idea of what to expect for the next quarter's release.
STVN Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
277.87M
2.38%
7.05%
Gross Margin
28.05%
-10.84%
-0.04%
Operating Margin
16.35%
-18.05%
18.65%
Net Margin
10.80%
-22.64%
36.02%
EPS
0.11
-21.43%
37.50%
No Data Available
STVN Earnings Analysis
Stevanato Group S.p.A. Corporation (STVN.N) Earnings Conference Call
Positive
Biopharmaceutical Revenue Increase: 1. Revenue Growth: Stevanato Group reported a 2% increase in revenue for Q3 2024, reaching €277.9 million, driven by a 6% growth in the Biopharmaceutical and Diagnostic Solutions Segment.
High-Value Solutions Revenue Growth: 2. High-Value Solutions Demand: Revenue from high-value solutions grew 17% year-to-date compared to last year, indicating strong demand for high-value syringes and other product categories.
Capacity Expansion Milestone: 3. Successful Capacity Expansion: The Fishers facility achieved a major milestone by launching commercial production and generating its first commercial revenue in Q3 2024, with plans for further validation activities.
Latina Project Profitability: 4. Latina Facility Profitability: The Latina project became profitable at the gross profit level in Q3 2024, demonstrating improved utilization and efficiency in production.
Market Recovery Indicators: 5. Positive Market Signals: The company continues to see positive signals in the market, with expectations for vial orders to begin picking up at the end of 2024, indicating a gradual recovery in demand.
Negative
Gross Profit Margin Decline: 1. Declining Gross Profit Margin: The gross profit margin decreased to 26.8% in Q3 2024, impacted by ongoing vial destocking and inefficiencies in new manufacturing ramp-ups.
Engineering Revenue Decline: 2. Significant Revenue Decline in Engineering Segment: Revenue from the Engineering segment decreased by 15% to €44.8 million, with gross profit margin dropping to 15.6% due to higher costs and project delays.
Revised EBITDA Forecast: 3. Lowered Full-Year Guidance: The company has lowered its full-year 2024 guidance for adjusted EBITDA to a range of €257 million to €263 million, reflecting increased costs in the Engineering segment and validation activities.
Negative Cash Flow Report: 4. Negative Free Cash Flow: The company reported negative free cash flow of €28.4 million in Q3 2024, indicating cash outflows exceeding cash generated from operations.
Inventory Overstock Concerns: 5. High Inventory Levels: As of September 30, inventory levels were higher compared to December 31, 2023, suggesting potential overstocking issues amid declining demand.
STVN FAQs
How does STVN typically perform around its earnings report dates?
Is Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
STVN Earning Call Sentiment
Stevanato Group S.p.A. (STVN) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
STVN.N
2.1%Positive
Despite some growth in the BDS segment and high-value syringes, the overall sentiment is negative due to declining revenue in the Engineering segment, operational inefficiencies, and negative free cash flow. The Q&A reveals uncertainty about recovery in vial orders and destocking, and management's reluctance to provide clear guidance adds to the negative sentiment. The reduced EBITDA and EPS guidance further contribute to a negative outlook.
